Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

237

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Breast Cancer
Interventions
DRUG

Anastrozole

1mg/Day Oral

DRUG

Risedronate Sodium

35mg/week, oral

Trial Locations (35)

Unknown

Research Site, Palm Springs

Research Site, Jacksonville

Research Site, New Orleans

Research Site, New York

Research Site, Raleigh

Research Site, Cleveland

Research Site, Pittsburgh

Research Site, Houston

Research Site, Burnaby

Research Site, Edmonton

Research Site, Montreal

Research Site, Québec

Research Site, Vancouver

Research Site, Bordeaux

Research Site, Caen

Research Site, Lyon

Research Site, Saint-Cloud

Research Site, Saint-Herblain

Research Site, Athens

Research Site, Irakleio

Research Site, Goes

Research Site, Ijssel

Research Site, Nijmegen

Research Site, The Hague

Research Site, Bloemfontain

Research Site, Cape Town

Research Site, Tygerberg

Research Site, Pamplona

Research Site, Pontevedra

Research Site, Seville

Research Site, Valencia

Research Site, Belfast

Research Site, Bolton

Research Site, Dundee

Research Site, Luton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY